# Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

> **NCT06192160** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 315 (estimated)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Isoniazid
- **DRUG:** Rifampicin
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol
- **DRUG:** Bedaquiline
- **DRUG:** Pretomanid
- **DRUG:** Linezolid
- **DRUG:** TBI-223
- **DRUG:** Sutezolid
- **DRUG:** TBI-223
- **DRUG:** Sutezolid

## Key facts

- **NCT ID:** NCT06192160
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2026-11-11
- **Final completion:** 2027-08-11
- **Target enrollment:** 315 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192160, "Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06192160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*